New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
2003 · Expert Opinion on Investigational Drugs · 56 citations
https://doi.org/10.1517/13543784.12.4.531
F
Frank P. Bymaster
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
1.1K
Citations
10
h-index
10
i10-index
Frank P. Bymaster is an academic researcher from Eli Lilly (United States). The author has contributed to research in topics: Receptor Mechanisms and Signaling & Neurotransmitter Receptor Influence on Behavior & Neuroscience and Neuropharmacology Research. The author has an h-index of 10, co-authored 9 publications.
Papers by this author
worksNeurochemical Effects of the M1 Muscarinic Agonist Xanomeline
1993 · 0 citations
Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor
2002 · Journal of Pharmacology and Experimental Therapeutics · 609 citations
https://doi.org/10.1124/jpet.301.3.1020
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity
2011 · Synapse · 30 citations
https://doi.org/10.1002/syn.21531
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat